Altamira Therapeutics reported asset growth of -11.64% for the quarter ended Jun 2025. These growth metrics cover 15 quarters of results from Dec 2017 through Jun 2025, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Dec2017 | Dec2018 | Dec2019 | Jun2020 | Dec2020 | Jun2021 | Dec2021 | Jun2022 | Dec2022 | Jan2023 | Jun2023 | Dec2023 | Jun2024 | Dec2024 | Jun2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | |||||||||||||||
| Assets Growth (1y) | -48.05% | -44.87% | -5.14% | -30.30% | 147.70% | 207.80% | -11.07% | -24.86% | -67.45% | -67.53% | -64.37% | 33.58% | 16.95% | -5.16% | -11.64% |
| Assets Growth (3y) | -35.23% | 9.01% | 27.84% | 17.25% | -10.50% | -10.57% | -6.25% | -27.15% | -32.10% | -25.57% | -28.33% | ||||
| Assets Growth (5y) | -9.76% | -17.81% | -17.85% | -1.90% | -7.65% | -1.90% | -3.16% | ||||||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -52.04% | -64.16% | -73.93% | -99.29% | 793.37% | 21,793.90% | -91.57% | -95.75% | -98.45% | -98.46% | -85.88% | 4,288.45% | 18.73% | 36.41% | -94.26% |
| Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) | -64.48% | -5.84% | -41.87% | -59.62% | -77.32% | -77.34% | 9.50% | -61.44% | -80.76% | -2.49% | -78.74% | ||||
| Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) | -49.22% | -74.44% | -74.46% | -33.15% | -59.40% | -6.92% | -38.30% | ||||||||
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | -28.83% | -86.66% | 99.74% | 181.59% | -23.14% | -56.36% | -100.00% | -100.00% | -0.99% | -8.63% | 6.12% | 9.43% | -10.09% | 8,433,500.41% | 10,301,600.00% |
| Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) | -42.55% | -41.06% | -96.83% | -96.28% | -97.49% | -97.56% | -97.31% | -97.18% | -96.58% | 4,404.03% | 4,515.09% | ||||
| Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) | -92.13% | -91.60% | -91.73% | -87.20% | -86.25% | 7.76% | 12.47% | ||||||||
| Total Debt Growth (1y) | -14.89% | -85.90% | -78.96% | 5,200.98% | 4,974.32% | -30.92% | -98.22% | ||||||||
| Total Debt Growth (3y) | -61.42% | -55.91% | 301.56% | -41.63% | -55.62% | ||||||||||
| Total Debt Growth (5y) | -59.96% | -8.52% | -9.32% | -39.51% | 52.30% |
Pull Altamira Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=CYTOF&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "CYTOF", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=CYTOF&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();